Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Study on postoperative analgesia effect of lidocaine patient-controlled intravenous analgesia in patients undergoing laparoscopic colorectal tumor surgery

ABSTRACT: Interventions: Experimental group :PCIA: lidocaine 72mg/kg and normal saline are made into 300lm.;Control group:PCIA: sufentanil 2µg/kg and normal saline are made into 300lm. Primary outcome(s): Analgesic effect Study Design: Parallel

DISEASE(S): Colorectal Tumor

PROVIDER: 84982 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Effects of lidocaine on the expression of rat spinal cord

Project description:This study aimed to explore the possible mechanism of lidocaine-induced neurotoxicity. A total of 40 rats were randomly assigned to 4 groups (n = 10 per group): control group; sham group, received only intrathecal catheter insertion; saline group, received an intrathecal injection of saline; and lidocaine group, received an intrathecal injection of 10% lidocaine. Neurobehavioral tests were performed on rats in each group before injection and 1, 2, 3, and 4 days after the intrathecal injection. On the fourth day, after completing neurobehavioral tests, the spinal cords of all rats from L2 to L6 were removed and immediately stored in liquid nitrogen. In the control and lidocaine groups, parts of the spinal cord tissues of three rats were selected for gene microarray analysis.Based on the results of the gene chip analysis,Five rats in each group underwent real-time quantitative polymerase chain reaction (PCR) and five Western blot analysis to verify Differentially expressed genes at the mRNA transcription and protein levels. The aim of gene chip analysis is to screen potential genes involved in lidocaine-induced neurotoxicity.

2019-09-05 | GSE136833 | GEO

a Pilot Study of Lidocaine Infusion for Postoperative Analgesia in Elderly Patients With Colorectal Cancer Surgery

Project description:patients who meet the enrollment criteria will be randomized 1:1:1:1 to the different doses of lidocaine or the placebo group. In the lidocaine groups, at the beginning of surgery, lidocaine 0.5mg/kg, 1.0mg/kg, and 1.5mg/kg per hour were continuously infused (using ideal body weight) respectively during the whole procedure. In contrast, the control group was infused with the same dose of normal saline. All the infusion procedures will be stopped at the end of surgery

| 2735240 | ecrin-mdr-crc

Effects of dexmedetomidine combined with epidural anesthesia on intestinal function and postoperative outcomes of patients undergoing laparoscopic colorectal cancer surgery

Project description:Interventions: Control group (CON group):Intravenous and inhalation combined anesthesia, equal amount of normal saline; Sufentanil PCIA.;Dexmedetomidine group (DEX group):Dexmedetomidine group (DEX group): intravenous anesthesia was assisted by intravenous of DEX with the loading dose of 0.5~1.0 microgram/kg completed within 10 minutes and maintenance infusion of 0.5~1.0 microgram /kg/h until the end of the operation. Sufentanil + DEX to implement PCIA.; Epidural group (EP group):Intravenous Inhalation Combined with epidural anesthesia, ropivacaine + sufentanil PCEA;DEX + EP group:Intravenous anesthesia assisted by intravenous DEX combined with epidural anesthesia, ropivacaine + DEX PCEA. Primary outcome(s): Peristalsis time after operation;Oral feeding time after operation Study Design: Parallel

| 47743 | ecrin-mdr-crc

Effect of perioperative dexmedetomidine on postoperative sleep quality and rehabilitation of patients undergoing laparoscopic radical gastrectomy for gastric cancer and colorectal cancer

Project description:Interventions: Group C:Normal saline was used during operation and sufentanil was used in PCIA after operation;Group D1:Dexmedetomidine was used during operation and sufentanil was used in PCIA after operation;Group D2:Dexmedetomidine was used during operation, and sufentanil combined with dexmedetomidine was used in PCIA after operation Primary outcome(s): The sleep quality of patients;Night Sleep;The first occurrence time of bowel sounds;Intraperative drug consumption and hemodynamics;The delirium score of patients;Postoperative pain score and PCIA compression times;adverse reaction Study Design: Parallel

| 2761814 | ecrin-mdr-crc

Effect of Esketamine on Preventing Depression After Resection of the Colorectal Cancer: A Randomized Clinical Trial

Project description:Interventions: experimental group :Eesketamine + Sufentanil PCIA group (Group E, n=60, esketamine 1.0 mg / kg and sufentanil 2.0 µ g / kg);control group:Sufentanil PCIA group (Group C, n=60, sufentanil 2.0 µ g / kg) Primary outcome(s): HAMD grade;VAS grade;Postoperative adverse effects;Brain-derived neurotrophic factor(BDNF) Study Design: Parallel

| 106072 | ecrin-mdr-crc

Protective effect of dexmedetomidine combined with epidural block on postoperative analgesia and early cognitive impairment in elderly patients after radical resection of colorectal cancer: a randomized controlled trial

Project description:Interventions: Dexmedetomidine group:Patients were injected with 0.6 µg/kg/h dexmedetomidine by intravenous injection after anesthesia induction to 30 min before the end of the surgery.;Epidural blockade group:The epidural blockade was conducted by epidural injection of 2% lidocaine;Combined group:Patients were treated with both dexmedetomidine and epidural blockade as described above;Control group:Patients were injected with 0.6 µg/kg/h of normal saline Primary outcome(s): MMSE scores at different time points after surgery;Ramsay scores at different time points after surgery;VAS scores at different time points after surgery;PCIA pressing times Study Design: Randomized parallel controlled trial

| 2682196 | ecrin-mdr-crc

Clinical observation of different doses of nalmefene combined with hydromorphone on postoperative analgesia following colorectal cancer surgery

Project description:Interventions: Low dose Group:hydromorphone 0.1mg/kg +nalmefene 3µg/kg +normal saline to 100ml;Ultra Low Dose Group:hydromorphone 0.1mg/kg +nalmefene 1µg/kg +normal saline to 100ml;Control Group:hydromorphone 0.1mg/kg +normal saline to 100ml Primary outcome(s): Postoperative pain intensity Study Design: Parallel

| 2693953 | ecrin-mdr-crc

Lidocaine and bupivacaine downregulate MYB protein and LncRNA DANCR through interaction with miR-187-5p in MCF7 cells

Project description:In order to identify microRNAs (miRNAs) that were involved in the effects of anesthetics on breast cancer cells, Illumina next generation miRNA sequencing was performed to search for any differentially expressed miRNAs in responding to lidocaine and bupivacaine treatments in MCF7 breast cancer cells. The filtering criteria for identifying differentially expressed miRNAs in the lidocaine and bupivacaine groups were fold change ≥ 2.0X and P-value ≤ 0.05. In total, there were 1,228 significantly upregulated miRNAs in lidocaine group and 133 miRNAs in bupivacaine group. On the contrary, there were 25 significantly downregulated miRNAs in lidocaine group and 36 miRNAs in bupivacaine group.

2022-01-13 | GSE171282 | GEO

Efficacy of systemic lidocaine on quality of recovery in patients undergoing colorectal endoscopic submucosal dissection

Project description:Interventions: lidocaine group:Patients received an intravenous bolus injection of lidocaine 1.5 mg/kg over 10 min before induction of anesthesia, followed by a continuous infusion of 2 mg/kg/h until the end of the surgery.;control group:Patients received a perioperative 0.9% saline infusion at the same rate as the lidocaine infusion. Primary outcome(s): Incidence of postoperative cognitive recovery Study Design: Parallel

| 35544 | ecrin-mdr-crc

RNA-sequencing of lidocaine treatment on rat dorsal root ganglion neurons

Project description:We conducted RNA-sequencing of lidocaine hydrochloride in treating rat dorsal root ganglion neurons to detect lidocaine’s effect of transcriptome profiling changes compared with control.

2019-11-09 | GSE140162 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data